Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diagnostic algorithms for neuromuscular diseases

R Mañon-Espaillat1, S Mandel

  • 1Department of Neurology, Jefferson Medical College, Philadelphia, Pennsylvania, USA.

Clinics in Podiatric Medicine and Surgery
|February 4, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brain catalase in the streptozotocin-rat model of sporadic Alzheimer's disease treated with the iron chelator-monoamine oxidase inhibitor, M30.

Journal of neural transmission (Vienna, Austria : 1996)·2014
Same author

Evaluation of the peripheral nervous system in disability management: practical aspects in lower back pain.

Journal of back and musculoskeletal rehabilitation·2014
Same author

Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain.

Neuroscience·2011
Same author

Oxidative stress indices in Parkinson's disease : biochemical determination.

Methods in molecular medicine·2011
Same author

Collection of blood in heparinized tubes does not alter the molecular distribution or forms of IGFBP-3 and IGF.

Endocrine·2010
Same author

Determination of melanotropic and thyrotropic hormones in Riehl's melanosis; frequency of bowel disorders in this condition.

Annales de dermatologie et de syphiligraphie·2010
Same journal

Lesser Toe Pathology: Challenges, Controversies, and Advances.

Clinics in podiatric medicine and surgery·2026
Same journal

Pathology of the Lesser Toes.

Clinics in podiatric medicine and surgery·2026
Same journal

Principles of Lesser Toe and Metatarsophalangeal Joint Reconstruction for Complex and Revision Surgery of the Forefoot.

Clinics in podiatric medicine and surgery·2026
Same journal

Biomechanical Problems Related to Lesser Toes Dysfunction and Amputation.

Clinics in podiatric medicine and surgery·2026
Same journal

Is It Necessary to Repair the Plantar Plate in the Management of Metatarsophalangeal Joint Instability?

Clinics in podiatric medicine and surgery·2026
Same journal

Lesser Metatarsophalangeal Joint Instability: Arthroscopic Treatment Alternatives.

Clinics in podiatric medicine and surgery·2026
See all related articles

Neuromuscular disorders cause significant disability. Management includes supportive care, physical therapy, and medications for pain, spasticity, and specific conditions like myasthenia gravis.

Area of Science:

  • Neurology
  • Internal Medicine

Background:

  • Neuromuscular disorders present with diverse symptoms including weakness, pain, and autonomic dysfunction.
  • These conditions significantly impact patient quality of life and daily functioning.

Purpose of the Study:

  • To provide an overview of current management strategies for various neuromuscular disorders.
  • To highlight therapeutic options for symptom control and disease modification.

Main Methods:

  • Review of established treatments for neuromuscular conditions.
  • Categorization of therapies based on disorder type (e.g., motor neuron disorders, neuropathies, myopathies).

Main Results:

  • Supportive measures, physical therapy, and respiratory support are broadly beneficial.

Related Experiment Videos

  • Pharmacological interventions include antiepileptics and antidepressants for pain, benzodiazepines and baclofen for spasticity.
  • Specific treatments are lacking for motor neuron disorders and muscular dystrophies.
  • Immunosuppression is key for inflammatory neuropathies and myopathies.
  • Cholinesterase inhibitors and immunosuppression aid in myasthenia gravis.
  • Toxic and endocrine myopathies require addressing the causative agent or underlying condition.

    • Conclusions:

    • While specific cures are often unavailable, comprehensive management strategies can alleviate symptoms and improve function in neuromuscular disorders.
    • Tailored treatment approaches, including addressing underlying causes and employing targeted therapies, are crucial for effective patient care.